Precision Medicine in Oncology®

Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations, and emphasized the need for further research in this area to determine which patients are most likely to benefit from certain therapies based on their molecular profiles.

Saketh Guntupalli, MD, highlights data supporting PARP inhibitors as the standard-of-care frontline therapy, strategies for the management of PARP-related toxicities, and the importance of testing for HRD and BRCA status in patients with ovarian cancer.

Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.

A doublet comprised of the bispecific innate cell engager AFM24 and atezolizumab had a tolerable safety profile and elicited responses in patients with advanced EGFR-expressing solid tumors.

HPV status has broad applicability across head and neck cancers, whereas the clinical utility of PD-L1 expression remains a more nuanced question.

Driven by his twin passions for music and science, Louis M. Staudt, MD, PhD, has made a career out of reading between the notes.

Ritu Salani, MD, MBA, discusses the continued evolution of molecular profiling in endometrial cancer, advances in immunotherapy for endometrial and cervical cancer, and ongoing research in gynecologic cancers.

Alexander E. Perl, MD, MS, discusses the implications of the updated ELN guidelines, how genetic testing guides treatment in this disease, and ongoing research investigating novel AML targets such as NPM1 mutations or KMT2A translocations.

Daniel J. George, MD, discusses the clinical benefits of evaluating phenotype in metastatic castration-resistant prostate cancer.

Daniel J. George, MD, discusses the importance of understanding mutations in prostate cancer.

The FDA has issued an accelerated approval for the Agilent Resolution ctDx FIRST assay for plasma as a companion diagnostic for adagrasib.

Daniel J. George, MD, discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations.

The FDA has granted a breakthrough therapy designation to revumenib for the treatment of adult and pediatric patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

Enrollment has been paused for a phase 1 trial investigating the peptide-drug conjugate TH1902 for the treatment of patients with sortilin-expressing cancers.

Olaparib plus durvalumab and bevacizumab led to prolonged survival and disease control without causing additive toxicity in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer.

The FDA has approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as detected by an FDA-approved test.

Anna C. Pavlick, DO, discusses the sequencing of immunotherapy vs targeted therapy in BRAF-mutated melanoma.

Benjamin P. Levy, MD; Bhuvana Ramkumar, MD; and Neil Morganstein, MD, discuss the challenges with tissue testing facing care teams, as well as multilevel hurdles in procurement, analysis of results, and insurance.

Daniel J. George, MD, discusses the clinical implications use of key trials in metastatic castration-resistant prostate cancer.

Molecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods are taken up in clinical practice.

The FDA has granted an orphan drug designation to vebreltinib for the treatment of patients with non–small cell lung cancer harboring MET genomic tumor aberrations.

The FDA has approved the VENTANA FOLR1 RxDx assay, the first immunohistochemistry companion diagnostic test to help identify patients with epithelial ovarian cancer who are eligible for treatment with mirvetuximab soravtansine-gynx.

All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications.

As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.

Neal Shore, MD, FACS, highlights the effect of genetic testing on the treatment paradigm of prostate cancer and the evolving treatment landscape for metastatic castration resistant prostate cancer.